文献速递前列腺癌

雄激素剥夺治疗对Gleason 8与Gleason 9-10前列腺癌总生存的影响

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-10-24

结果显示ADT与Gleason 8患者OS显著改善相关(aHR 0.78,95%CI 0.70-0.87,p<0.001),但与Gleason 9-10患者OS无显著相关(aHR 0.96,95%CI 0.84-1.11,p=0.6),交互作用显著(p=0.020)。

要点

  • Gleason 8患者接受ADT与OS改善显著相关(aHR 0.78,95%CI 0.70-0.87,p<0.001)。
  • Gleason 9-10患者接受ADT与OS无显著相关(aHR 0.96,95%CI 0.84-1.11,p=0.6)。
  • Gleason评分越高,ADT与OS关联的aHR越大(pinteraction=0.042)。

核心结论

  • ADT对Gleason 8前列腺癌有显著生存优势,而Gleason 9-10疾病从ADT获得的生存获益较小。
  • Gleason评分越高,ADT与OS关联的获益越小。
  • 应考虑通过临床试验入组或添加新型抗雄激素药物或多西他赛来强化Gleason 9-10患者的治疗。

主要发现

  • 多变量分析显示ADT与Gleason 8患者OS显著改善相关(aHR 0.78,95%CI 0.70-0.87,p<0.001)。
  • ADT与Gleason 9-10患者OS无显著相关(aHR 0.96,95%CI 0.84-1.11,p=0.6)。
  • ADT与OS的关联存在显著交互作用(pinteraction=0.020)。
  • Gleason评分(8、9、10)越高,ADT与OS关联的aHR越大(pinteraction=0.042)。

关键数值与推荐

  • ADT与Gleason 8患者OS改善显著相关(aHR 0.78,95%CI 0.70-0.87,p<0.001)。
  • ADT与Gleason 9-10患者OS无显著相关(aHR 0.96,95%CI 0.84-1.11,p=0.6)。
  • ADT与OS关联的交互作用显著(pinteraction=0.020)。
  • Gleason评分与ADT和OS关联的交互作用显著(pinteraction=0.042)。

临床怎么用

  • 对Gleason 8前列腺癌患者,ADT联合外照射放疗与OS改善相关。
  • 对Gleason 9-10患者,ADT的生存获益较小,可考虑临床试验入组或添加新型抗雄激素药物或多西他赛以强化治疗。

局限性

  • 随访时间相对较短(中位4.0年)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While the addition of androgen deprivation therapy (ADT) to external beam radiation therapy (EBRT) is known to improve overall survival (OS) in Gleason 8-10 (Grade Group 4-5) prostate cancer (PCa), it has been hypothesized that Gleason 9-10 disease, which is less differentiated than Gleason 8 disease, may be less sensitive to ADT. OBJECTIVE: To examine the association between ADT and OS for Gleason 8 versus Gleason 9-10 PCa. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of 20 139 men from the National Cancer Database with localized or locally advanced, Gleason 8-10 PCa who received EBRT. Data were collected from 2004 to 2012. INTERVENTION: ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cox proportional hazards regression was used to examine the association between ADT and OS. RESULTS AND LIMITATIONS: Overall, 9509 (78%) of the 12 160 men with Gleason 8 disease and 6908 (87%) of the 7979 men with Gleason 9-10 disease received ADT. On multivariable analysis, ADT was associated with a significant improvement in OS for Gleason 8 patients (adjusted hazard ratio 0.78, 95% confidence interval 0.70-0.87, p<0.001) but not for Gleason 9-10 patients (adjusted hazard ratio 0.96, 95% confidence interval 0.84-1.11, p=0.6), with a significant interaction (pinteraction=0.020). A higher Gleason score (8, 9, 10) correlated with an increased adjusted hazard ratio for the association between ADT and OS (pinteraction=0.042). Our study may be limited by the relatively short follow-up (median of 4.0 yr). CONCLUSIONS: In contrast to the significant survival advantage of ADT for Gleason 8 disease, our results suggest that Gleason 9-10 disease derives less survival benefit from ADT and that a higher Gleason score predicts lesser benefit. Consideration should be given to treatment intensification for Gleason 9-10 patients through enrollment in clinical trials or potentially adding novel antiandrogens or docetaxel, which have shown efficacy in both castration-resistant and castration-sensitive settings. PATIENT SUMMARY: In this study, we examined the effect of androgen deprivation therapy (ADT) for Gleason 8 (Grade Group 4) versus Gleason 9-10 (Grade Group 5) prostate cancer. We found that Gleason 9-10 disease may derive a smaller survival benefit from ADT than Gleason 8 disease.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Yang DD, Mahal BA, Muralidhar V, et al. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2018. PMID: 30554605. doi:10.1016/j.eururo.2018.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。